MTVA MTVA
Company Profile ↓Company Overview
MTVA (MTVA) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -77.27% |
| 6 Months: | -21.58% |
| 3 Months: | +4.93% |
| 1 Month: | -5.70% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.14 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 91.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | -1.59M | -1.61M | -2.37M | -2.51M | -2.23M | -1.84M | -3.40M | -7.23M | -7.50M | -10.52M | -8.54M | -6.57M | -7.06M | -6.53M | -5.91M | -3.30M | -2.45M | -1.89M | -3.65M | -4.75M | -2.39M | -3.06M | -3.33M | -3.93M | -3.46M | -2.88M | -3.22M | -3.10M | -2.52M | -3.81M | -3.89M | -6.88M | -10.08M | -6.26M | -3.89M | -4.30M | -3.48M | -4.03M |
| Net Income | -196.00K | -2.28M | -1.61M | -2.57M | -2.57M | -2.10M | -1.39M | -3.88M | -7.21M | -7.50M | -10.50M | -8.67M | -6.75M | -7.22M | -6.68M | -6.08M | -3.66M | -2.46M | -1.90M | -3.62M | -4.73M | -2.38M | -3.05M | -3.32M | -3.92M | -3.46M | -2.88M | -3.30M | -3.11M | -2.60M | -734.00K | -3.82M | -6.71M | -10.05M | -5.65M | -3.67M | -4.00M | -3.38M | -3.82M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.19 | -0.15 | -0.18 | -4.66 | -3.24 | -3.72 | -3.50 | -0.51 | -0.15 | -0.75 | -1.32 | -1.85 | -0.55 | -3.93 | -0.26 | -0.14 | -0.79 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 186.00K | - | - | - | - | - | - | - | - | - | - | - | - | 8.07M | 4.52M | 2.33M | 2.32M | 1.91M | 2.10M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Oct 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | -266.00K | -8.08M | -14.70M | -33.12M | -15.49M | -20.18M | -29.72M | -15.30M | -19.63M | -15.89M | -28.81M | -13.71M |
| Net Income | -124.00K | -320.00K | -9.03M | -14.59M | -33.41M | -15.53M | -21.31M | -29.68M | -15.28M | -13.97M | -12.47M | -27.59M | -12.97M |
| Diluted EPS | - | - | - | - | - | - | - | -1.83 | -19.81 | -43.42 | -2.46 | -39.13 | -7.35 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | 21.55M | 6.80M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 4.49M | 24.75M | 19.02M | 3.82M | 14.47M | 10.97M | 16.80M | 33.53M | 22.78M | 16.26M | 11.12M |
| Total Equity | -264.00K | -531.00K | -12.38M | 20.63M | 25.00K | -13.29M | 12.29M | 7.20M | 14.60M | 21.75M | 16.68M | 7.93M | 5.33M |
| Cash & Equivalents | 3.00K | 317.00K | 3.62M | 24.03M | 18.47M | 2.85M | 13.91M | 10.09M | 16.39M | 33.36M | 22.43M | 16.02M | 10.28M |
| Total Liabilities | - | - | 8.92M | 4.12M | 15.08M | 360.00K | 2.18M | 3.77M | 2.20M | 11.78M | 6.10M | 8.33M | 5.79M |
| Current Liabilities | - | - | 8.92M | 4.12M | 6.39M | 219.00K | 2.08M | 3.69M | 2.16M | 11.78M | 5.96M | 8.27M | 5.65M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.43M | -11.04M | -26.90M | -14.45M | -7.04M | -10.76M | -15.13M | -11.71M | -10.80M | -24.71M | -15.70M |
| Investing Cash Flow | - | - | - | -3.00K | -6.06M | 69.00K | -586.00K | 8.00K | -50.00K | -8.00K | -2.00K |
| Financing Cash Flow | 8.74M | 31.46M | 21.34M | 17.25M | 24.17M | 6.86M | 22.03M | 28.68M | -80.00K | 18.30M | 9.96M |
| Capital Expenditure | - | - | - | -3.00K | -214.00K | -4.00K | -3.00K | - | -50.00K | -8.00K | -2.00K |
| Free Cash Flow | - | - | - | -14.45M | -7.25M | -10.77M | -15.14M | - | -10.85M | -24.72M | -15.70M |
Ratios (Annual)
Figures in %.
| Metric | Oct 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | - | 60.3% | 72.9% | -70.7% | -133,660.0% | 116.9% | -173.4% | -412.0% | -104.7% | -64.2% | -74.7% | -347.9% | -243.3% |
| ROCE % | - | - | 182.4% | -71.2% | -262.3% | -430.0% | -162.9% | -408.6% | -104.5% | -90.2% | -94.4% | -360.6% | -250.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MTVA
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks were lower late Thursday afternoon, with the NYSE Healthcare Index shedding 0.5% a
MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that all enrolled active patients in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for the treat…
OTC Markets Life Sciences Investor Forum: MetaVia CEO HH Kim and CFO Marshall Woodworth with Zacks SCR's David Bautz
NASDAQ: MTVA Greg Young: Hello and welcome to the Life Sciences Investor Forum . On behalf of OTC Markets and our co-host, Zacks Small Cap Research , we are very pleased you have joined us. The first presentation of the day is from MetaVia …
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available…
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.comNEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today an…
MTVA: Vanoglipel and DA-1726 Data Presented at ADA 2026 Scientific Sessions
By David Bautz, PhD NASDAQ: MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Multiple Presentations for DA-1726 and Vanoglipel at ADA 2026 On June 8, 2026, MetaVia, Inc. (NASDAQ: MTVA) announced the presentation of new late-breaking …
MTVA — Frequently Asked Questions
What is the current share price of MTVA?
As of 2026-08-05 17:25 PDT, MTVA trades at $1.49 on NASDAQ/NYSE. Its 52-week range is $0.97 to $16.50.
What is the P/E ratio of MTVA?
MTVA trades at a trailing price-to-earnings (P/E) ratio of -0.20.
Is MTVA a good stock to buy?
This page provides a data-driven analysis of MTVA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.